GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tango Therapeutics Inc (NAS:TNGX) » Definitions » Total Equity

TNGX (Tango Therapeutics) Total Equity : $199.52 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tango Therapeutics Total Equity?

Tango Therapeutics's total equity for the quarter that ended in Dec. 2024 was $199.52 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


Tango Therapeutics Total Equity Historical Data

The historical data trend for Tango Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tango Therapeutics Total Equity Chart

Tango Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
38.60 344.75 249.48 253.11 199.52

Tango Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 253.11 264.45 247.67 229.17 199.52

Tango Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Tango Therapeutics's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=316.492-116.975
=199.52

Tango Therapeutics's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=316.492-116.975
=199.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tango Therapeutics Total Equity Related Terms

Thank you for viewing the detailed overview of Tango Therapeutics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Tango Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
201 Brookline Avenue, Suite 901, Boston, MA, USA, 02215
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Executives
Douglas Barry officer: See Remarks TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Adam Crystal officer: See Remarks C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Barbara Weber director, officer: Chief Executive Officer C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Daniella Beckman officer: Chief Financial Officer C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Mace Rothenberg director 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Third Rock Ventures Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Mva Investors, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Lesley Ann Calhoun director C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
John B Ketchum director TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Trv Gp Vi, Llc director 201 BROOKLINE AVE., BOSTON MA 02215
Third Rock Ventures Gp Vi, L.p. director 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Vi, L.p. director 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116